Department of Surgery, Division of Surgical Oncology, California University of Science and Medicine, Colton, CA 92324, USA.
Department of Surgery, Division of Surgical Oncology, The Ohio State University Medical School, Columbus, OH 43210, USA.
Hematol Oncol Clin North Am. 2025 Feb;39(1):25-35. doi: 10.1016/j.hoc.2024.08.012.
Hepatic resection for patients with isolated breast cancer liver metastases (BCLM) is associated with prolonged disease-free interval and better overall survival in highly selected patients. Patients with limited disease who are not candidates for surgery benefit from ablative therapies for isolated breast cancer metastasis in addition to systemic chemotherapy. In the era of modern effective systemic chemotherapy for BCLM, local regional therapies are warranted, yet only in well-selected patients following discussion in a multidisciplinary setting. This article reviews data related to hepatic resection and ablative therapies of BCLM, as well as long-term outcomes of women treated with these approaches.
孤立性乳腺癌肝转移(BCLM)患者行肝切除术与高度选择的患者无病间期延长和总体生存改善相关。对于不适合手术的局限性疾病患者,除全身化疗外,还可受益于孤立性乳腺癌转移的消融治疗。在现代有效治疗 BCLM 的全身化疗时代,局部区域治疗是合理的,但仅在多学科讨论后选择合适的患者中进行。本文回顾了与 BCLM 的肝切除术和消融治疗相关的数据,以及采用这些方法治疗的女性的长期结果。